| Name | Title | Contact Details |
|---|
Osiris Therapeutics, Inc. is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation. In Biosurgery, we harness the ability of cells and novel constructs to promote the body`s natural healing. The goals are to improve surgical outcomes and offer better treatment options for patients and physicians. We like a challenge, so the focus is in areas where we believe we can have a significant impact. Difficult indications and challenging cases are targeted. Osiris has been studying tissue engineering since the beginning, and its dedicated team conducted groundbreaking research in the field. The work in bone led to the development of the successful product Osteocel, now owned by NuVasive Inc. Now, application of these technologies is being expanded beyond bone, to soft tissues, such as cartilage and tendon, and also wound healing.
Surmodics partners with the world`s leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. Following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. Throughout its transformation, Surmodics` mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges
Astute Medical is committed to improving patient outcomes through the identification and validation of unique biomarkers. Our measurement methods help rapidly assess high-risk acute conditions and diseases. By incoporating useful clinical tools, we help healthcare professionals provide rapid, accurate and life-saving responses.
In the simplest sense, we`re a company that creates solutions. More specifically, we design novel access device technology for neurovascular interventions and unmet clinical needs. Because in the precious seconds that surround a stroke emergency, clinicians need technology that delivers.
Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.